4-(5-Methoxycarbonyl-isoxazol-3-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester | 169605-40-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(5-Methoxycarbonyl-isoxazol-3-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Methyl 3-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methoxy]-1,2-oxazole-5-carboxylate
• CAS: 169605-40-7
• 化学式: C₁₆H₂₄N₂O₆
• 分子量: 340.376
• InChiKey: JMBVTUUENLOHJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  91.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-(5-Methoxycarbonyl-isoxazol-3-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester 在 甲醇 、 lithium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 1.0h， 生成 3-[[1-[(2-Methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methoxy]-1,2-oxazole-5-carboxylic acid
  参考文献：
  名称：

  EP2006286

  摘要：

  公开号：
• 作为产物：
  描述：

  4-哌啶甲醇 在 N,N-二异丙基乙胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 4-(5-Methoxycarbonyl-isoxazol-3-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Synthesis and antiplatelet effects of an isoxazole series of glycoprotein IIb/IIIa antagonists

  摘要：

  Despite the excellent in vitro potency of a series of benzamide glycoprotein IIb/IIIa antagonists, which have been reported previously, poor in vivo potency in the inhibition of platelet aggregation was observed when the most potent inhibitor XU057 was dosed intravenously to dogs. In this communication, we report that replacement of the benzamide in XU057 with an isoxazolecarboxamide resulted in significant improvement in in vivo potency. More importantly, the analogue XU065 showed an excellent oral antiplatelet effect in dogs. (C) 1998 The DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00637-4

文献信息

• [EN] COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSES CONTENANT DES TERMINAISONS BASIQUES ET ACIDES UTILES EN TANT QU'ANTAGONISTES DES RECEPTEURS DE FIBRINOGENE
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：WO1995018111A1

  公开（公告）日：1995-07-06

  (EN) This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.(FR) Nouveaux composés contenant des terminaisons basiques et acides, compositions pharmaceutiques contenant lesdits composés, procédés pour préparer lesdits composés et procédés d'utilisation desdits composés, seuls ou en combinaison avec d'autres agents thérapeutiques, afin d'inhiber l'agrégation plaquettaire, afin de servir d'agents thrombolytiques, et/ou afin de traiter des troubles thromboemboliques.

  该发明涉及新型化合物，其含有碱性和酸性末端，含有这种化合物的制药组合物，制备这种化合物的方法，以及使用这些化合物的方法，单独或与其他治疗剂联合使用，用于抑制血小板聚集，作为溶栓剂以及治疗血栓栓塞性疾病。
• ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11 BETA -HYDROXYSTEROID DEHYDROGENASE TYPE I
  申请人：Shionogi Co., Ltd.

  公开号：EP2006286A2

  公开（公告）日：2008-12-24

  Disclosed is a compound useful as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R1 is a group of the formula: -C(=O)NR4R5, (wherein R4 and R5 are each independently, hydrogen, optionally substituted alkyl or the like) or a group of the formula: -NR6C(=O)R7, (wherein R6 and R7 are each independently, hydrogen, optionally substituted alkyl or the like), X and Y are each independently -0- or the like, Z is a bond or the like, R2 is optionally substituted alkyl, optionally substituted alkenyl or the like, R3 is optionally substituted alkyl, optionally substituted alkenyl or the like.

  本发明公开了一种可用作 11β- 羟类固醇脱氢酶 1 型抑制剂的化合物。 一种由式表示的化合物： 其药学上可接受的盐或溶液、 其中 R1 是式中的基团：-C(=O)NR4R5、 (其中 R4 和 R5 各自独立地为氢、任选取代的烷基或类似物）或 式中的基团-NR6C(=O)R7、 (其中 R6 和 R7 各自独立地为氢、任选取代的烷基或类似基团）、 X和Y各自独立地为-0-或类似物、 Z 是键或类似物、 R2 是任选取代的烷基、任选取代的烯基或类似物、 R3 是任选取代的烷基、任选取代的烯基或类似物。
• EP2006286
  申请人：——

  公开号：——

  公开（公告）日：——
• ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I
  申请人：Ogawa Tomoyuki

  公开号：US20090131491A1

  公开（公告）日：2009-05-21

  Disclosed is a compound useful as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is a group of the formula: —C(═O)NR 4 R 5 , (wherein R 4 and R 5 are each independently, hydrogen, optionally substituted alkyl or the like) or a group of the formula: —NR 6 C(═O)R 7 , (wherein R 6 and R 7 are each independently, hydrogen, optionally substituted alkyl or the like), X and Y are each independently —O— or the like, Z is a bond or the like, R 2 is optionally substituted alkyl, optionally substituted alkenyl or the like, R 3 is optionally substituted alkyl, optionally substituted alkenyl or the like.
• US5563158A
  申请人：——

  公开号：US5563158A

  公开（公告）日：1996-10-08